Back to Peptide Pedia
Growth Hormone
Well Researched

CJC-1295 (No DAC)

CJC

Short-acting GHRH analog.

Also known as: Mod GRF 1-29, CJC-1295 without DAC

Research dose range100 mcg per dose (research models)
Route studiedSubcutaneous
Study duration1–3× daily, multi-week studies
Storage2–8 °C reconstituted

Overview

CJC-1295 without DAC (Mod GRF 1-29) is a growth-hormone-releasing hormone analog studied for its short half-life and pulsatile GH-release profile.

Key research findings

The short-acting GHRH analog (often called Mod-GRF 1-29 or CJC-1295 without DAC), studied for producing clean, pulsatile GH release that more closely mimics natural rhythms than the long-acting DAC version. Commonly paired with a GHRP such as ipamorelin.

Mechanism of action

Binds GHRH receptors on the pituitary to trigger a sharp, short-lived pulse of growth-hormone release.

Molecular information

Weight3,368 Da
Length30 amino acids
TypeShort-acting GHRH analog (Mod-GRF 1-29)

GHRH(1-29) with four stabilizing substitutions but no albumin-binding DAC linker.

Pharmacokinetics

Peak: ~0.25 hoursHalf-life: ~0.5 hoursCleared: ~6 hours
Peak · 1hHalf-life · 4h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

  • Pulsatile GH-release research
  • GH-axis studies
  • Secretagogue-combination investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Standard referenceAmount: 100 mcgFrequency: 1–3× dailyRoute: Subcutaneous
GHRP-combination referenceAmount: 100 mcg + GHRPFrequency: Per doseRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

  1. Acute (per dose)

    Clean GH pulse reported within ~30 minutes; short duration preserves natural rhythm.

  2. Week 2–4

    Cumulative IGF-1 elevation reported with consistent dosing.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

Ipamorelin

Classic GHRH + GHRP pulsatile-release pairing.

Compatible

CJC-1295 (with DAC)

Redundant GHRH-receptor activation.

Avoid combination

GHRP-6

Synergistic GH pulses when co-administered.

Requires timing

Tesamorelin

Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.

Use caution

MK-677

Different mechanisms - MK-677 provides continuous ghrelin stimulation while CJC-1295 offers pulsatile GHRH

Compatible

Hexarelin

Can be combined but monitor for excessive GH elevation due to Hexarelin's potency

Monitor

How to reconstitute

Important

Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Avoid shaking to preserve the peptide.

  1. 1Allow the vial to reach room temperature (15–20 minutes).
  2. 2Swab the stopper with alcohol and let it air dry.
  3. 3Add bacteriostatic water slowly down the vial wall.
  4. 4Swirl gently until dissolved into a clear solution.
  5. 5Refrigerate at 2–8 °C and protect from light.
Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

  • Generally well tolerated; transient flushing/head-rush and injection-site reactions reported.
  • Shorter action than the DAC version means more frequent dosing in study designs.

References & further reading

Modified GRF(1-29) GHRH analog pharmacology (review)

Preclinical/humanGHRHpulsatile GH

Review of the short-acting modified GHRH analog and its pulsatile GH-releasing profile.

View study

Topics

ghrhgrowth hormoneshort-acting

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level
Well Researched

Substantial peer-reviewed research across multiple models.

Quick reference
Dose range100 mcg per dose (research models)
RouteSubcutaneous
Duration1–3× daily, multi-week studies
Storage2–8 °C reconstituted
Half-life~0.5 hours
Available at Reviva

CJC-1295 (No DAC) is stocked as a research-grade compound, ≥99% by HPLC, third-party verified.

View in catalogue